<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317471</url>
  </required_header>
  <id_info>
    <org_study_id>PLAG-CS-Ga-01</org_study_id>
    <nct_id>NCT02317471</nct_id>
  </id_info>
  <brief_title>Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96</brief_title>
  <official_title>Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cure&amp;Sure Biotech Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of autologous gp96
      treatment of gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events related to gp96 immunotherapy</measure>
    <time_frame>participants will be followed from the day of the first vaccination to the 30th day after the last vaccination.</time_frame>
    <description>A complete blood count will be requested before the first vaccination, after the second vaccination and after the last vaccination to monitor the side effect of gp96 immunotherapy. And blood chemistries will also be requested at the same time point for the same reason.
And other adverse events related to gp96 immunotherapy will be recorded according to the NCI-CTCAE 3.0 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in antigen specific T cells</measure>
    <time_frame>within 3 days before the first vaccination and within 3 days after the 10th vaccination</time_frame>
    <description>Tumor antigen specific T cells will be determined by IFN-γ Enzyme-linked immunosorbent spot using the autologous tumor cell lysis as the antigen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>gp96 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous gp96 vaccination + basal treatment for gastric cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oxaliplatin+S-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous gp96 vaccination</intervention_name>
    <description>Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.
gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion.</description>
    <arm_group_label>gp96 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin+S-1</intervention_name>
    <description>Treatment will be start at the 5th week after the surgery.
S-1: 40~60mg bid，d1~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles.</description>
    <arm_group_label>gp96 group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>Oxaliplatin(Sanofi-aventis), S-1(Taiho)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Disease characteristics: Histologically confirmed gastric carcinoma: clinical stage
             III (according to the Japanese gastric cancer classification), must have undergone
             radical resection

          2. Able to read and understand the informed consent document, must sign the informed
             consent

          3. Age: 18 to 75 years old

          4. Availability of at least 0.5 g tumor sample

          5. ECOG ≤1；life expectancy &gt;=12 weeks, able to comply with study-related procedures

          6. Adequate bone marrow function including the absence of lymphopenia (ANC &gt; 1,500/ mm3;
             Hemoglobin &gt; 10g/dL ; platelet count &gt;100,000/mm3), adequate liver function (serum
             glutamic oxaloacetic transaminase/ aspartate aminotransferase [AST], alanine amino
             transferase [ALT] &lt;2.5 times institutional upper limit of normals [IULNs] and
             bilirubin (total) &lt;1.5 times IULN), and adequate renal function (BUN and creatinine
             &lt;1.5 times IULNs)

          7. Normal heart function

          8. NOT participate in ANY other clinical trials within 4 weeks prior to vaccination.

        Exclusion Criteria:

          1. Unable to get the informed consent

          2. Female patients who are pregnant or breastfeeding

          3. Progression prior to treatment as determined by the principal investigator

          4. Transplant recipient

          5. Patients currently diagnosed with Human Immunodeficiency Virus or other active
             uncontrolled infection

          6. Unstable or severe intercurrent medical conditions

          7. Patient with allergic constitution

          8. Patients with any systemic disease needed to be treated with immunosuppressant or
             Corticosteroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zheng Peng, MD</last_name>
    <phone>086-10-66938028</phone>
    <email>zihpeng@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng Peng, MD</last_name>
      <phone>086-10-66938028</phone>
      <email>zihpeng@sina.com</email>
    </contact>
    <investigator>
      <last_name>Lin Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2014</study_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Lin Chen</investigator_full_name>
    <investigator_title>Director of the general surgery department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

